Provided by Tiger Trade Technology Pte. Ltd.

XTL Biopharmaceuticals

2.79
+0.09003.33%
Volume:21.64K
Turnover:57.99K
Market Cap:6.60M
PE:-0.82
High:2.79
Open:2.60
Low:2.60
Close:2.70
52wk High:10.28
52wk Low:2.01
Shares:2.37M
Float Shares:1.29M
Volume Ratio:1.46
T/O Rate:1.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4144
EPS(LYR):-1.1996
ROE:-577.13%
ROA:-240.56%
PB:-140.43
PE(LYR):-2.33

Loading ...

XTL Biopharmaceuticals Adjourns Extraordinary Shareholder Meeting to June 29, 2026

TIPRANKS
·
Yesterday

XTL Biopharmaceuticals Gets Nasdaq Noncompliance Notice

MT Newswires Live
·
May 23

XTL Biopharmaceuticals Faces Added Nasdaq Delisting Risk Over Late 2025 Annual Report

TIPRANKS
·
May 23

XTL Announces Receipt of Staff Delist Determination from Nasdaq

GlobeNewswire
·
May 23

XTL Biopharmaceuticals Calls June 22, 2026 Meeting to Approve Psyga Bio Acquisition and Capital Raise

TIPRANKS
·
May 16

XTL Biopharmaceuticals Wins Conditional Nasdaq Listing Reprieve Tied to Psyga Bio Deal

TIPRANKS
·
May 07

XTL Biopharmaceuticals to Acquire PsygaBio in All-Stock Deal to Expand Psychedelic Drug Pipeline

TIPRANKS
·
Apr 29

XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies

GlobeNewswire
·
Apr 29

XTL Biopharmaceuticals trading halted, news pending

TIPRANKS
·
Mar 25

XTL Biopharmaceuticals to Change ADS Ratio

MT Newswires Live
·
Mar 21

XTL Biopharmaceuticals to Implement One-for-Four ADS Reverse Split Effective March 25, 2026

TIPRANKS
·
Mar 21

Beyond Air announces termination of NeuroNOS agreement with XTL

TIPRANKS
·
Mar 10

XTL Biopharmaceuticals Faces Nasdaq Delisting After “Public Shell” Determination

TIPRANKS
·
Feb 28

XTL Biopharmaceuticals gets delisting letter from Nasdaq, to request hearing

TIPRANKS
·
Feb 28

XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing

GlobeNewswire
·
Feb 28

XTL Biopharmaceuticals Advances NeuroNOS Acquisition and Plans $2 Million Private Placement to Address Nasdaq Equity Deficiency

TIPRANKS
·
Jan 28

XTL Biopharmaceuticals Faces Subsidiary Insolvency Filing, Reviews $1.5 Million Loan Exposure

TIPRANKS
·
Jan 24

XTL Biopharmaceuticals Flags Nasdaq Equity Deficiency, Given Deadline to Regain Compliance

TIPRANKS
·
Jan 24

XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders’ Equity Deficiency

GlobeNewswire
·
Jan 24

ADRs Hold Steady; XTL Biopharmaceuticals Ltd. Climbs 57%

Dow Jones
·
Jan 14